Is ALLO stock safe? | Glauxie AI

Q: Is ALLO stock safe?

Allogene Therapeutics, Inc. (ALLO) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO David D. Chang. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops,... Employees: 152.

Q: What are the risks of investing in ALLO?

Identify key risks of investing in ALLO — debt, competition, volatility, and sector headwinds.

Q: Is ALLO a good long-term investment?

Evaluate ALLO as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does ALLO have?

Review ALLO total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is ALLO stock safe?

🦉

Allogene Therapeutics, Inc. (ALLO)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODavid D. Chang

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product...

Key Executives

Name	Title
Annie Yoshiyama	SVP & Corporate Controller
Arie S. Belldegrun	Co-Founder & Executive Chairman
Benjamin Beneski	Senior Vice President & Chief Technical Officer
Christine Cassiano	Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer
David D. Chang	Co-Founder, President, Chief Executive Officer & Director
Earl Douglas	Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

ALLO Profile Financials

What are the risks of investing in ALLO? Is ALLO a good long-term investment? How much debt does ALLO have?